Publications

Journal Article
Research Support, Non-U.S. Gov't
Epublish 183 citations
Electronic publication date
December 18, 2019

View on Pubmed.gov 29500339 | View on doi.org 10.1038/s41419-...

Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation.

Search for publications in this journal Cell Death Dis - 9(3):351

  • Tao-Tao Tang 1
  • Lin-Li Lv

    Search for this expert
    2
  • Ming-Ming Pan

    Search for this expert
    1
  • Yi Wen

    Search for this expert
    1
  • Bin Wang

    Search for this expert
    1
  • Zuo-Lin Li 1
  • Min Wu

    Search for this expert
    1
  • Feng-Mei Wang

    Search for this expert
    1
  • Steve D Crowley

    Search for this expert
    3
  • Bi-Cheng Liu

    Search for this expert
    4

Abstract

Inflammation is a major contributor to the pathogenesis of ischemic acute kidney injury (AKI), which complicates the post-operative outcomes of large numbers of hospitalized surgical patients. Hydroxychloroquine (HCQ), a well-known anti-malarial drug, is commonly used in clinical practice for its anti-inflammatory actions. However, little is known about its role in renal ischemia/reperfusion (I/R) injury. In the current study, mice were subjected to I/R injury and HCQ was administered for seven days by gavage prior to surgery. In parallel, HK-2 human renal proximal tubule cells were prophylactically treated with HCQ and then were exposed to hypoxia/reoxygenation (H/R). The results showed that HCQ significantly attenuated renal dysfunction evidenced by blunted decreases in serum creatinine and kidney injury molecular-1 expression and the improvement of HK-2 cell viability. Additionally, HCQ markedly reduced macrophage and neutrophil infiltration, pro-inflammatory cytokine production, and NLRP3 inflammasome activation. Mechanistic studies showed that HCQ could inhibit the priming of the NLRP3 inflammasome by down-regulating I/R or H/R-induced NF-κB signaling. Moreover, HCQ reduced cathepsin (CTS) B, CTSD and CTSL activity, and their redistribution from lysosomes to cytoplasm. CTSB and CTSL (not CTSD) were implicated in I/R triggered NLRP3 inflammasome activation. Notably, we found that HCQ attenuated renal injury through downregulation of CTSB and CTSL-mediated NLRP3 inflammasome activation. This study provides new insights into the anti-inflammatory effect of HCQ in the treatment of AKI.

References

Int Rev Exp Pathol. 1984;26:85-106

Cell Death Dis. 2013 Jun 27;4:e694

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20364-71

J Pharmacol Exp Ther. 2013 Sep;346(3):465-72

Cited by 183 citations (total)

Journal Article Research Support, Non-U.S. Gov't

Role of Parkin-mediated mitophagy in the protective effect of polydatin in sepsis-induced acute kidney injury.

Electronic publication date May 15, 2021

Search for publications in this journal J Transl Med

Youguang Gao [...] Bo Lin et al.

BACKGROUND

We have reported that polydatin (PD) alleviates mitochondrial dysfunction in rat models of sepsis-induced acute kidney injury (SI-AKI), but the...

Journal Article

Necrostatin-1 Attenuates Renal Ischemia and Reperfusion Injury via Meditation of HIF-1α/mir-26a/TRPC6/PARP1 Signaling.

Electronic publication date August 20, 2019

Search for publications in this journal Mol Ther Nucleic Acids

Bingbing Shen [...] Hongwen Zhao et al.

Necroptosis, oxidative stress, and inflammation are major contributors to the pathogenesis of ischemic acute kidney injury. Necrostatin-1 (Nec-1), an inhibitor...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances